All In Biotech

NDA 022173 · Cheplapharm

Zyprexa Relprevv

Olanzapine Pamoate · Intramuscular

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Dec 11, 2009

Approved uses

1

Original approval plus efficacy supplements

Registered trials

495

150 Phase 3, 32 recruiting

FAERS reports

40,828

31,555 serious, 4,498 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME and INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Patients are at risk for severe sedation (including coma) and/or delirium after each injection and must be observed for at least 3 hours in a certified healthcare setting with ready access to emergency response services. Because of this risk, ZYPREXA RELPREVV is available only through a restricted distribution program called ZYPREXA RELPREVV REMS and requires prescriber, healthcare setting, patient, and pharmacy enrollment. ( 2.1 , 5.1 , 5.2 , 10.2 , 17 ) Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ZYPREXA...

What it is approved for

From the label in effect May 19, 2026.

ZYPREXA RELPREVV is available only through a restricted distribution program [see Warnings and Precautions ( 5.2 )] . ZYPREXA RELPREVV must not be dispensed directly to a patient. For a patient to receive treatment, the prescriber, healthcare setting, patient, and pharmacy must all be enrolled in the ZYPREXA RELPREVV REMS. To enroll, call 1-877-772-9390. ZYPREXA ® RELPREVV™ is a long-acting atypical antipsychotic for intramuscular injection indicated for the treatment of schizophrenia. ( 1.1 ) Efficacy was established in two clinical trials in patients with schizophrenia: one 8-week trial in adults and one maintenance trial in adults. ( 14.1 ) 1.1 Schizophrenia ZYPREXA RELPREVV is indicated for the treatment of schizophrenia. Efficacy was established in two clinical trials in patients with schizophrenia: one 8-week trial in adults and one maintenance trial in adults [see Clinical Studies ( 14.1 )] .

Mechanism: The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 405MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 210MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription
  • ZYPREXA RELPREVV · OLANZAPINE PAMOATE EQ 300MG BASE/VIAL · SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olanzapine Pamoate" as an intervention, any sponsor and status, largest first.

All 495 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diabetes mellitus4,878
  • weight increased4,144
  • drug ineffective1,953
  • off label use1,900
  • pancreatitis1,734
  • hypertension1,688
  • type 2 diabetes mellitus1,639
  • anxiety1,571
  • nausea1,466
  • somnolence1,410
  • fatigue1,388
  • insomnia1,351

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,651
20052,497
20063,074
20072,993
20081,331
20092,936
20102,552
20112,496
20121,837
20131,224
20141,275
20155,915
20161,368
20171,532
20181,381
20191,372
20201,176
2021936
2022960
2023790
2024580
2025583
2026368

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zyprexa Relprevv (Olanzapine Pamoate)

2024 spending

$1.4M

Beneficiaries

252

1,394 claims

Per beneficiary

$5,699

$911.52 per unit

View as table
YearSpending
2020$5,449,379
2021$5,246,409
2022$4,806,762
2023$4,070,202
2024$1,436,272

Part B: Zyprexa Relprevv (Olanzapine Pamoate) · HCPCS J2358

2024 spending

$64K

Beneficiaries

338

406 claims

Per beneficiary

$190

2024 ASP limit $2.92 per unit

View as table
YearSpending
2020$51,476
2021$184,574
2022$231,116
2023$0
2024$64,067

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.